WO1992012234A1

WO1992012234A1 - Dried, rotary disc fatty acid microencapsulated bacteria

Info

Publication number: WO1992012234A1
Application number: PCT/US1991/002118
Authority: WO
Inventors: William M. Rutherford; Jack E. Allen; Herman Wade Schlameus; Donald J. Mangold; William W. Harlowe, Jr.
Original assignee: Pioneer Hi-Bred International, Inc.
Priority date: 1990-12-31
Filing date: 1991-03-29
Publication date: 1992-07-23
Also published as: PL172912B1; BR9107280A; YU83491A; DE69126037T2; DK0565522T3; JPH06503705A; JP2573892B2; BG97909A; CA2099617A1; RU2096452C1; BG61399B1; CS144691A3; HU214778B; CA2099617C; ATE152767T1; CZ280816B6; HUT68380A; SK279880B6; HU9301855D0; DE69126037D1

Abstract

Dried, rotary disc microencapsulated capsules of bacteria and process of preparing said microencapsulated bacteria being fatty acid microencapsulated.

Description

DRIED, ROTARY DISC FATTY ACID MICROENCAPSULATED BACTERIA BACKGROUND OF THE INVENTION

It is known that certain bacteria are potentially beneficial when added to animal feeds.

These bacteria are beneficial in that they supply a natural intestinal micro-flora. Some companies offer for sale probiotics which contain desirable bacteria. Probiotics, however, do have some difficulty in maintaining a stable product.

Typically, the probiotic is used at a fairly small level, added to feed at perhaps a 1% level.

However, unused probiotic containing feed or feed additive product is often stored by the farmers for long periods of time. This storage many times is under conditions where there is some moisture. In many instances there is just enough moisture that the bacteria are activated or start to grow, but yet there is an insufficient amount of moisture to sustain them. As a result they die. Thus, the activity of the probiotic is stopped. In other instances, the addition of antibiotics to the probiotic containing feed or feed additive adversely interacts with the bacteria, particularly if there are small amounts of moisture present and thus again bacteria are killed. Thus, there is a significant problem of long term storage stability for probiotics. In another environment, where the probiotic is added to, for example chicken feed, it is common to pelletize the material with the probiotic added before pelletizing. Moisture from steam used during pelletization partially activates the bacteria, but may, as a result of insufficient moisture to sustain them, kill them. Also heat during pelletization may- kill them. Then, too, there is the problem of the acid environment of the stomach potentially inactivating bacteria before they really reach the intestine. Thus, there is a continuing need for probiotics which will release the organisms only at the proper time in the intestine, without early release due to moisture conditions or adverse pH conditions such as exist in the digestive tract anterior to the small intestine.

It is a primary objective of the present invention to provide probiotics suitable for animal feed ration addition which contains bacteria that are microencapsulated in a special rotary encapsulation technique using free fatty acid encaps lant.

Another objective of the present invention is to provide a probiotic which has stability at levels within the range of from 3 months to 6 months without any significant organism count reduction. Another objective of the present invention is to provide a process of rotary icroencapsulation of dried bacteria which provides individual spheres of coated bacteria as opposed to clumped, clusters of spheres of coated bacteria.

Another objective of the present invention is to provide rotary disc microencapsulated dried bacteria which are free flowing, and easily processible with animal feed rations.

An even further objective of the present invention is to provide microencapsulated Enteroococcus faceiu .

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1, 2 and 3 show graphically the stability of encapsulated strains using stearic acid encapsulant.

SUMMARY OF THE INVENTION

Discrete particles of fatty acid encapsulated bacteria, preferably stearic acid encapsulated Enterococcus faceium are provided. Freeze dried bacterial culture is mixed with from 50% to over 90% by weight of a stearic acid melt and thereafter rotary disc encapsulated. DETAILED DESCRIPTION OF THE INVENTION

This invention relates to freeze dried, rotary disc microencapsulated capsules of bacteria. Preferably the capsules are free fatty acid microencapsulated. There are two significant and important aspects of this invention that distinguish it from other prior encapsulated bacteria. In the first instance it is the nature of the encapsulant, that is a fatty acid. In the second instance it is the nature of the encapsulation process, which here does not use a conventional spray drying technique but instead a method of rotary disc microencapsu- lation. It is the coaction of these two distinct steps which provide for the highly stable probiotic of the present invention. If either step alone is used, the stability is not achieved.

The preferred encapsulating agent is a , - to r, . free fatty acid. While mixtures of fatty acids may be employed, it is preferred that a single pure free fatty acid be employed. It is also preferred that the free fatty acid be an unsaturated fatty acid, with the most preferred being stearic acid.

Generally speaking, it is important that the fatty acid have a melting point less than 75°C, preferably within the range of 40"c to 75°C. It must, of course, be solid at room temperature in order to be an effective encapsulant. All free fatty acids falling within the range of chemical description heretofore given will meet these requirements.

The precise bacteria encapsulated is not critical. However, the precise one selected will depend upon the probiotic being formed. Generally speaking, for use in this invention, Enterococcus faceium is the preferred bacteria. It should be understood that other bacteria such as Lactobacil- lus. Bacillus, etc. may also be employed. Mixtures of strains may be employed as well as individual strains. In order to enhance the product stability, the bacteria are typically freeze-dried bacteria as placed in the product. Thus, they can be revived by moisture addition.

In the microencapsulant, made in accordance with the process discussed below, the microencapsulated particles generally comprise from about 50% to over 90% by weight of the fatty acid component with the balance being bacterial culture. The preferred range is from about 60% to about 75% fatty acid. If too little fatty acid is used, the coating will be inadequate for protection. On the other hand, if too much is used, the coating will be too thick and results in inadequate release in the gut. The encapsulation process as used in this invention is a rotary disc microencapsulation process. Generally speaking in the rotary disc technology, a slurry of the bacteria and fatty acid components are thoroughly mixed with the mixture being added at a uniform rate onto the center of a rotating stainless steel disc. It is there flung outwardly as a result of centrifugal force. It is then collected in a cooling chamber maintained at ambient conditions or slightly lower, sized and readied for packaging.

While rotary disc encapsulation is known, it is not known for use with bacteria for microencapsu¬ lation of freeze dried bacteria. Generally speaking for descriptions of rotary disc encapsulation, see a paper by Johnson, et al. of the Southwest Research Institute of San Antonio, in the Journal of Gas Chromotography, October, 1965, pages 345-347. In addition, a rotary disc encapsulator suitable for use in this invention is described in detail in United States Letters Patent, Sparks, 4,675,140, issued June 23, 1987 and entitled "Method For Coating Particles For Liquid Droplets the disclosure of which is incorporated herein by reference.

It is important to note that rotary micro¬ encapsulation provides a distinctly different product - 1 -

than does conventional tower spray drying. In conventional tower spray drying there is a tendency for particles to cluster, for the coating to be uneven, and thus for the stability of the product to be significantly effected perhaps from days to weeks. When rotary microencapsulation, particularly with encapsulating agents used in this invention is used, the stability of the resulting bacteria, even when subjected to some moisture and antibiotics, will be for from three to six months.

When the microencapsulant free fatty acid material of the present invention is used within the ranges hereinbefore expressed, the encapsulator typically employing a 4" rotary disc can be run at the rate of from 2000 rpm to 4000 rpm, preferably about 2500 rpm to 3200 rpm with a feed rate of from 50 grams to 200 grams per minute. The preferred conditions presently known are use of stearic acid, use of Enterococcus faceium, a four inch rotary disc, 3000 rpm and a feed rate of 100 grams per minute with a bacteria/stearic acid slurry of 35% bacteria, 65% stearic acid. When this is done, a product having a particle size of from 75 microns to 300 microns will be achieved, with a preferred level of less than 250 microns. The following examples are offered to further illustrate, but not limit, the process of the present invention. The examples are described in connection with Figures 1, 2 and 3.

Example 1 Example 1 correlates with Figure 1. It shows the product stability of two different strains of Enterococcus faceium with temperatures of 4°C and 27°C. As illustrated in Figure 1, it shows a stability of the encapsulated strains of Entero¬ coccus faceium, with the encapsulation being by the rotary disc encapsulator using stearic acid with a level of 35% culture weight. Conditions of encap¬ sulation were as previously described herein, namely a 35/65 bacteria stearic acid slurry at a temperature of 60°C, using a four inch rotary disc, operating at 3000 rpm and a feed rate of 100 grams per minute. The culture was encapsulated, placed in heat sealed vapor barrier pouches and destructively sampled weekly for CFU determination. It can be seen that the product of the invention maintained excellent organism colony forming unit (CFU) counts out to storage times aS long as 70 days.

Example 2 Example 2 is to be interpreted in connection with Figure 2. The figure shows the stability of individual encapsulated strains when mixed in a typical feed ration in the presence of three poultry antibiotics. The ration consisted of the following: 54% five cracked corn 26% soybean meal 2% fish meal moisture content: 12% 1.5% dicalcium phosphate

1% limestone 5.5% soy oil Three antibiotics were added at the following inclusion rates by weight: Deccox 6% (454 ppm) , Salinomycin (50 ppm) and monensin sodium (120 ppm). Culture was added to the mixture at a level to deliver approximately 1x10 CFU/gm feed (100-150 gm/ton) . Feed was packaged in heat sealed bags and incubated at room temperature. Samples were taken weekly for CFU determination. The graph of Figure 2 illustrates the excellent stability.

Example 3 Example 3 is to be interpreted in conjunction with Figure 3. It shows the stability of the encapsulated Enterococcus faceium mixture in feed in the presence of different antibiotics. The ration consisted of 60% fine cracked corn, 38% soybean meal and 2% limestone with a moisture content of about 14%. Culture was added to a level of approximately 10 CFU/gm feed and mixed. Ten pound aliquots were stored in sealed bags at 20 C and sampled weekly for 16 weeks. The antibiotics were included in the ration at the following levels:

Bacitracin methylene disalicylate 50 g /ton

Carbadox 50 gm/ton

Chlortetracycline 200 gm/ton

Lasalocid 30 gm/ton

Lincomycin 100 gm/ton

Neomycin 140 gm/ton

Oxytetracycline 150 gm/ton

Sulfamethazine 100 gm/ton

Tylosin 100 gm/ton

Virginiamycin 20 gm/ton

ASP250 100 gm/ton

Table 1 is a list of the minimum times for a 1 log loss in colony forming units (CFU) .

Table 1

Time in days for loss of 1 log CFU counts at 20C in 14% moisture mash feed.

Example 4

In Example 4 the stability of product after pelletizing for use of a chicken feed product was determined. The microencapsulation conditions were as earlier described. The conditions used in this study were the following:

Crude Protein, not less than 18.0%

Crude Fat, not less than 5.0%

Crude Fiber, not more than 6.0% The pellets with and without the antibiotic (CTC 50 gm/ton) were made with the following ingredients and conditions.

Corn, SEM, whey, soy oil, dicalcium phosphate, limestone, trace mineral premix, vitamin premix, selenium, copper sulfate. Culture was added at approximately 5x10 CFU/gm feed (100-150 gm/ton).

Conditioning temperature was 70°C and the pellets out of the dye were 78°C.

Pellets were stored in unsealed bags and sampled weekly for CFU determination.

In each instance the pelletized product was not adversely affected in stability by the conditions of pelletizing. In particular, the pelletized product showed stability equal to the unpelletized product.

It therefore can be seen that the invention accomplishes all of its stated objectives.

Claims

What is claimed is:

1. Dried, rotary disc microencapsulated capsules of bacteria, said microencapsulated bacteria being fatty acid microencapsulated.

2. The microencapsulated bacteria of claim 1 wherein the fatty acid is a C,₂ to C₂₄ fatty acid.

3. The microencapsulated bacteria of claim 2 wherein the fatty acid is stearic acid.

4. The microencapsulated bacteria of claim 1 wherein the microencapsulated capsules are from about 50% to over 90% fatty acid, with the balance being bacterial culture.

5. The microencapsulated bacteria of claim 1 wherein the capsules have a particle size of from 75 microns to 300 microns.

6. The microencapsulated bacteria of claim 1 wherein the bacteria is Enterococcus faceium.

7. A process of preparing discrete individual capsules of fatty acid encapsulated bacteria, said process comprising: obtaining a bacterial culture of dried bacteria, mixing said freeze dried culture with from 50% to over 90% by weight of a fatty acid melt, and rotary disc encapsulating the mix of fatty acid and freeze dried bacteria in a rotary disc encapsulator to provide individually coated free flowing capsules of bacteria.

8. The process of claim 7 wherein the rotary disc is operating at an rpm within the range of 2000 rpm to 4000 rpm.

9. The method of claim 7 wherein the rotary disc is operating at a range of from 2500 rpm to 32000 rpm.

10. The method of claim 7 wherein feed rate of material into the rotary disc encapsulator is from 50 grams per minute to 200 grams per minute.

11. The method of claim 7 wherein the free fatty acid is C«₂ to C₂₄ fatty acid.

12. The method of claim 11 wherein the free fatty acid is stearic acid.

13. The method of claim 7 wherein the bacteria is Enterococcus faceium.